Shenzhen Chipscreen Biosciences Co. Ltd. Class ASSE: 688321

Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma

· Issued by Shenzhen Chipscreen Biosciences Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Top-line Analysis Data of Phase III Clinical Trial of Chidamide as the First-line Treatment for Diffuse Large B-cell Lymphoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment